Massive typhoid vaccine trial aims to curb fever in india
NCT ID NCT05500482
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This large study tested a typhoid conjugate vaccine called TyphiBEV in over 72,000 people aged 1 to 30 years in Vellore, India. The goal was to see if the vaccine reduces the number of confirmed typhoid fever cases in vaccinated communities compared to unvaccinated ones. The trial is now complete, and results will show how well the vaccine works in a real-world, high-burden setting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Typhoid conjugate vaccine (TyphiBEV)
- What this could lead to
- If successful, this vaccine could significantly reduce typhoid fever in high-burden areas, potentially saving lives and lowering healthcare costs.
- What could go wrong
- This is a completed Phase 4 trial, so results are available, but real-world effectiveness may vary. The vaccine may not work equally in all populations or settings.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPHOID FEVER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Christian Medical College Vellore
Vellore, Tamil Nadu, 632002, India
More trials for these conditions
Other studies related to the condition(s) this trial covers.